Treatment of primary and secondary liver tumors with an hepatic ablation cool-wet radiofrequency system: an interventional single-centre study.

Parc de Salut Mar- Hospital del Mar0 个研究点目标入组 102 人开始时间: 2015年6月14日最近更新: 2023年7月25日

适应症

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35013377/ (added 10/07/2023)

•1. Nodules suggestive of HCC or liver metastases from any source as abdominal CT, MRI or biopsy. The initial imaging test (CT or MRI) must not be older than 30 days (50 days maximum tolerance).
•2. Considered unresectable hepatic nodules in multidisciplinary and capable local treatment session
•3. Number of nodes: between 1 and 3
•4. Size of the nodules: between 1.5 and 4 cm
•5. Percutaneous, laparoscopic or open surgical access.
•6. Signature of informed consent
•7. Aged at least 18

•1. Higher than third level of Anesthetic risk measured by the classification of the American Association anesthesia (ASA IV)
•2. Carrier of a cardiac pacemaker
•3. Thrombocytopenia <50,000 / mL
•4. Suspicion of thrombosis portal by presence of tumor
•5. Child C and grading of hepatic failure
•6. Previous biliodigestive anatomosis
•7. Hepatic subcapsular nodule

发起方

Parc de Salut Mar- Hospital del Mar